LINC01089 Inhibits Tumorigenesis and Epithelial–Mesenchymal Transition of Non-small Cell Lung Cancer via the miR-27a/SFRP1/Wnt/β-catenin Axis

Xingkai Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Yushun Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Terry Z. Liu(University of California, Los Angeles), Shaolong Ju(Chinese Academy of Medical Sciences & Peking Union Medical College), Yicheng Liang(Chinese Academy of Medical Sciences & Peking Union Medical College), Boxuan Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Bing Wang(China Agricultural University), Fang Lv(Liaoning Normal University), Li Fang(Guangdong Pharmaceutical University), Minjun Du(Chinese Academy of Medical Sciences & Peking Union Medical College)
Frontiers in Oncology
November 17, 2020
10.3389/fonc.2020.532581
Cited by 27

Related Papers

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies
|Journal of Nanoparticle Research|2014|128
CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells
|Journal of Experimental & Clinical Cancer Research|2022|115
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis
|Bone|2019|110
The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles
|Medicine|2017|100